vs
Side-by-side financial comparison of Assertio Holdings, Inc. (ASRT) and TRANSCONTINENTAL REALTY INVESTORS INC (TCI). Click either name above to swap in a different company.
Assertio Holdings, Inc. is the larger business by last-quarter revenue ($13.5M vs $12.1M, roughly 1.1× TRANSCONTINENTAL REALTY INVESTORS INC). On growth, TRANSCONTINENTAL REALTY INVESTORS INC posted the faster year-over-year revenue change (2.3% vs -57.9%). Over the past eight quarters, TRANSCONTINENTAL REALTY INVESTORS INC's revenue compounded faster (0.7% CAGR vs -35.4%).
Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As o...
Transcontinental Realty Investors Inc. (TCI) is a U.S.-based real estate investment firm that owns, operates and develops a diversified portfolio of residential, commercial and mixed-use properties across core U.S. regional markets. It pursues long-term value growth via strategic property acquisitions, efficient asset management and tailored leasing solutions for individual and business tenants.
ASRT vs TCI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.5M | $12.1M |
| Net Profit | — | $8.3M |
| Gross Margin | — | — |
| Operating Margin | -86.7% | -28.9% |
| Net Margin | — | 68.8% |
| Revenue YoY | -57.9% | 2.3% |
| Net Profit YoY | — | 7577.8% |
| EPS (diluted) | $-4.54 | $0.97 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.5M | $12.1M | ||
| Q3 25 | $49.5M | $12.8M | ||
| Q2 25 | $29.2M | $12.2M | ||
| Q1 25 | $26.5M | $12.0M | ||
| Q4 24 | $32.2M | $11.8M | ||
| Q3 24 | $29.2M | $11.6M | ||
| Q2 24 | $31.1M | $11.8M | ||
| Q1 24 | $32.4M | $11.9M |
| Q4 25 | — | $8.3M | ||
| Q3 25 | $11.4M | $724.0K | ||
| Q2 25 | $-16.4M | $169.0K | ||
| Q1 25 | $-13.5M | $4.6M | ||
| Q4 24 | — | $108.0K | ||
| Q3 24 | $-2.9M | $1.7M | ||
| Q2 24 | $-3.7M | $1.5M | ||
| Q1 24 | $-4.5M | $2.5M |
| Q4 25 | -86.7% | -28.9% | ||
| Q3 25 | 23.2% | -10.9% | ||
| Q2 25 | -27.5% | -6.8% | ||
| Q1 25 | -50.0% | -5.3% | ||
| Q4 24 | -41.9% | -14.3% | ||
| Q3 24 | -10.4% | -14.4% | ||
| Q2 24 | -11.6% | -9.2% | ||
| Q1 24 | -13.4% | -11.2% |
| Q4 25 | — | 68.8% | ||
| Q3 25 | 23.1% | 5.6% | ||
| Q2 25 | -56.0% | 1.4% | ||
| Q1 25 | -51.1% | 38.5% | ||
| Q4 24 | — | 0.9% | ||
| Q3 24 | -10.0% | 14.7% | ||
| Q2 24 | -11.8% | 12.7% | ||
| Q1 24 | -13.9% | 21.4% |
| Q4 25 | $-4.54 | $0.97 | ||
| Q3 25 | $0.11 | $0.08 | ||
| Q2 25 | $-0.17 | $0.02 | ||
| Q1 25 | $-0.14 | $0.53 | ||
| Q4 24 | $-3.28 | $0.01 | ||
| Q3 24 | $-0.03 | $0.20 | ||
| Q2 24 | $-0.04 | $0.17 | ||
| Q1 24 | $-0.05 | $0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.4M | $89.0M |
| Total DebtLower is stronger | — | $210.8M |
| Stockholders' EquityBook value | $94.0M | $846.7M |
| Total Assets | $267.0M | $1.1B |
| Debt / EquityLower = less leverage | — | 0.25× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.4M | $89.0M | ||
| Q3 25 | $93.4M | $82.7M | ||
| Q2 25 | $98.2M | $73.5M | ||
| Q1 25 | $87.3M | $88.6M | ||
| Q4 24 | $100.1M | $99.7M | ||
| Q3 24 | $88.6M | $131.6M | ||
| Q2 24 | $88.4M | $127.5M | ||
| Q1 24 | $80.7M | $130.8M |
| Q4 25 | — | $210.8M | ||
| Q3 25 | — | $223.5M | ||
| Q2 25 | — | $212.4M | ||
| Q1 25 | — | $198.2M | ||
| Q4 24 | — | $181.9M | ||
| Q3 24 | — | $180.3M | ||
| Q2 24 | — | $177.4M | ||
| Q1 24 | $38.6M | $178.3M |
| Q4 25 | $94.0M | $846.7M | ||
| Q3 25 | $105.8M | $838.4M | ||
| Q2 25 | $93.3M | $837.7M | ||
| Q1 25 | $108.5M | $837.3M | ||
| Q4 24 | $121.1M | $832.3M | ||
| Q3 24 | $130.5M | $832.2M | ||
| Q2 24 | $132.2M | $830.4M | ||
| Q1 24 | $134.5M | $828.9M |
| Q4 25 | $267.0M | $1.1B | ||
| Q3 25 | $319.8M | $1.1B | ||
| Q2 25 | $273.8M | $1.1B | ||
| Q1 25 | $286.4M | $1.1B | ||
| Q4 24 | $284.7M | $1.1B | ||
| Q3 24 | $276.0M | $1.1B | ||
| Q2 24 | $279.4M | $1.0B | ||
| Q1 24 | $282.0M | $1.0B |
| Q4 25 | — | 0.25× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.25× | ||
| Q1 25 | — | 0.24× | ||
| Q4 24 | — | 0.22× | ||
| Q3 24 | — | 0.22× | ||
| Q2 24 | — | 0.21× | ||
| Q1 24 | 0.29× | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-30.0M | $-2.9M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | -0.35× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-30.0M | $-2.9M | ||
| Q3 25 | $-4.8M | $8.2M | ||
| Q2 25 | $19.1M | $-2.9M | ||
| Q1 25 | $-12.5M | $-7.4M | ||
| Q4 24 | $11.5M | $1.3M | ||
| Q3 24 | $-35.0K | $13.7M | ||
| Q2 24 | $7.4M | $-511.0K | ||
| Q1 24 | $7.5M | $3.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -0.35× | ||
| Q3 25 | -0.42× | 11.28× | ||
| Q2 25 | — | -17.24× | ||
| Q1 25 | — | -1.61× | ||
| Q4 24 | — | 12.13× | ||
| Q3 24 | — | 8.03× | ||
| Q2 24 | — | -0.34× | ||
| Q1 24 | — | 1.52× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASRT
| Products | $12.8M | 95% |
| Other | $719.0K | 5% |
TCI
Segment breakdown not available.
